文献リスト

1）Von Minckwitz G, du Bois A, Schmidt M, et al. Trastuzumab beyond progression in human epider­mal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. J Clin Oncol. 2009; 27: 1999-2006

2）Blackwell KL, Burstein HJ, Storniolo AM, et al. Randomized study of Lapatinib alone or in combi­nation with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol. 2010; 28: 1124-30

3）Arnold D, Andre T, Bennouna J, et al. Bevaci­zumab（BEV）plus chemotherapy（CT）conti­nued beyond first progression in patients with metastatic colorectal cancer（mCRC）previously treated with BEV plus CT: Results of a rando­mized phase III intergroup study（TML study）. J Clin Oncol. 2012; 30: abstr CRA3503

4）Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumo­urs: revised RECIST guideline（version 1.1）. Eur J Cancer. 2009; 45: 228-47

5）Grothey A, Sugrue MM, Purdie DM, et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large obser­vational cohort study（BRiTE）. J Clin Oncol. 2008; 26: 5326-34

6）Shukuya T, Takahashi T, Tamiya A, et al. Gefitinib plus paclitaxel after failure of gefitinib in non-small cell lung cancer initially responding to gefitinib. Anticancer Res. 2009; 29: 2747-51

7）Balak MN, Gong Y, Riely GJ, et al. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res. 2006; 12: 6494-501

8）Jackman DM, Holmes AJ, Lindeman N, et al. Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib. J Clin Oncol. 2006; 24: 4517-20

9）Shukuya T, Takahashi T, Naito T, et al. Continuous EGFR-TKI administration following radiotherapy for non-small cell lung cancer patients with isolated CNS failure. Lung Cancer. 2011; 74（3）: 457-61

10）Inomata M, Shukuya T, Takahashi T, et al. Continuous administration of EGFR-TKIs follow­ing radiotherapy after disease progression in bone lesions for non-small-cell lung cancer. Anticancer Res. 2011; 31: 4519-23

11）Weickhardt AJ, Scheier B, Burke JM, et al. Continuation of EGFR/ALK inhibition after local therapy of oligoprogressive disease in EGFR mutant （Mt） and ALK+ non-small cell lung cancer （NSCLC）. J Clin Oncol. 2012; 30: abstr 7526

12）http://clinicaltrials.gov, NCT01544179

13）http://clinicaltrials.gov, NCT01310036

14）Gridelli C, Bennouna J, de Castro J, et al. Randomized phase IIIb trial evaluating the conti­nuation of bevacizumab beyond disease progression in patients with advanced non-squamous non-small-cell lung cancer after first-line treatment with bevacizumab plus platinum-based chemotherapy: treatment rationale and protocol dynamics of the AvaALL （MO22097） trial. Clin Lung Cancer. 2011; 12（6）: 407-11

15）Takeda M, Okamoto I, Yamanaka T. Impact of treatment with bevacizumab beyond disease progression: a randomized phase II study of doce­taxel with or without bevacizumab after platinum-based chemotherapy plus bevacizumab in patients with advanced nonsquamous non–small cell lung cancer （WJOG 5910L） BMC. Cancer. 2012; 12（1）: 327

NPO医学中央雑誌刊行会 https://www.jamas.or.jp/ info@jamas.or.jp